Benchmark Upgrades American Science & Engineering Inc. (ASEI) to Buy; Order Provides Visibility
Tweet Send to a FriendGet Alerts ASEI Hot Sheet
Price: $60.14 -1.72%
Rating Summary:
0 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
0 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade ASEI Now!
Benchmark upgraded American Science & Engineering Inc. (NASDAQ: ASEI) from Hold to Buy with a price target of $67.00.
Analyst, Josephine Millward, said, "Our upgrade is based on improving visibility in FY13 for both service and cargo revenues, as well as potential upside in FY13/14 from a large Foreign Military Sales (FMS) order and from cargo screening services."
For an analyst ratings summary and ratings history on American Science & Engineering Inc. click here. For more ratings news on American Science & Engineering Inc. click here.
Shares of American Science & Engineering Inc. closed at $55.98 yesterday, with a 52 week range of $46.30-$78.99.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Josephine Millward, said, "Our upgrade is based on improving visibility in FY13 for both service and cargo revenues, as well as potential upside in FY13/14 from a large Foreign Military Sales (FMS) order and from cargo screening services."
For an analyst ratings summary and ratings history on American Science & Engineering Inc. click here. For more ratings news on American Science & Engineering Inc. click here.
Shares of American Science & Engineering Inc. closed at $55.98 yesterday, with a 52 week range of $46.30-$78.99.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
- Goldman Sachs Upgrades Abbott Labs (ABT) to Buy
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
Create E-mail Alert Related Categories
UpgradesLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

